{"name":"Sarepta Therapeutics, Inc.","slug":"sarepta-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"SRP-4045","genericName":"SRP-4045","slug":"srp-4045","indication":"Duchenne muscular dystrophy","status":"phase_3"},{"name":"AVI-6002","genericName":"AVI-6002","slug":"avi-6002","indication":"Other","status":"phase_1"},{"name":"SRP-4053","genericName":"SRP-4053","slug":"srp-4053","indication":"Duchenne muscular dystrophy (DMD) with mutations amenable to exon 53 skipping","status":"phase_3"},{"name":"AVI-4658 for Injection","genericName":"AVI-4658 for Injection","slug":"avi-4658-for-injection","indication":"Other","status":"phase_1"},{"name":"AVI-6003","genericName":"AVI-6003","slug":"avi-6003","indication":"Other","status":"phase_1"},{"name":"SRP-9003","genericName":"SRP-9003","slug":"srp-9003","indication":"Myotonic dystrophy type 1 (DM1)","status":"phase_3"}]}],"pipeline":[{"name":"SRP-4045","genericName":"SRP-4045","slug":"srp-4045","phase":"phase_3","mechanism":"SRP-4045 is a micro-dystrophin gene therapy that aims to treat Duchenne muscular dystrophy by providing a functional copy of the dystrophin gene.","indications":["Duchenne muscular dystrophy"],"catalyst":""},{"name":"AVI-6002","genericName":"AVI-6002","slug":"avi-6002","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SRP-4053","genericName":"SRP-4053","slug":"srp-4053","phase":"phase_3","mechanism":"SRP-4053 is an antisense oligonucleotide that modulates dystrophin production by promoting exon 53 skipping in Duchenne muscular dystrophy patients with mutations amenable to this approach.","indications":["Duchenne muscular dystrophy (DMD) with mutations amenable to exon 53 skipping"],"catalyst":""},{"name":"AVI-4658 for Injection","genericName":"AVI-4658 for Injection","slug":"avi-4658-for-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"AVI-6003","genericName":"AVI-6003","slug":"avi-6003","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"SRP-9003","genericName":"SRP-9003","slug":"srp-9003","phase":"phase_3","mechanism":"SRP-9003 is an antisense oligonucleotide that reduces production of DMPK protein by targeting mutant DMPK mRNA in myotonic dystrophy type 1.","indications":["Myotonic dystrophy type 1 (DM1)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiUkFVX3lxTE1MZWhHRmstY3hVSWdvYTFkZEgxeGU0WTh1T1IzbzJ1VzVBVEZna1BlQm9faW9tdnFaLVEtc1ZHeWlYN0djR3VWZ1k1bUl2VVlxNVE?oc=5","date":"2026-04-08","type":"pipeline","source":"Yahoo! Finance Canada","summary":"Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo! Finance Canada","headline":"Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History - Yahoo! Finance Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxQeVRtZktCcXZmSU9OUG1yajgtZkMtR3pHOS01YjA2c2NRRGxqaTA5N3FDelZ0QXVOa3NUd0VpSDh3VWRJYlh3UGVZX0V1VkdJSHZISXhJZDVxR0lEdkJ0NTRjdy1MZkJTVmNJaXZaYkxjRWZiN0dJQWtMVjFUQU1uNFJ6Vk5vdXljT3BCN2FxV3JWU1lBdl9TOFdpQ05UMFpNWEJnRlZ5WnFnWEwtRjIyV2VzbExUVE4ydUswOEdPdWp2b2JM?oc=5","date":"2025-11-25","type":"regulatory","source":"Fierce Pharma","summary":"Sarepta gets FDA's go-ahead to study immunosuppressive Elevidys regimen in bid to reverse label restriction - Fierce Pharma","headline":"Sarepta gets FDA's go-ahead to study immunosuppressive Elevidys regimen in bid to reverse label restriction","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxOWUgzcWstYWxpeUpyQ3pOdGRlY3J2RTdqeU1ZaEFQRXFRdXM3MEs0dWxYbmp3a0pLVmNpbTZiXzR5NHNSelRLekdTQjZ4eEJWZUtZZXdqWmV5bThwYVcyY29ZNzJ1U2V6SnlfMG9yWVk2aXZlY0xMZkY1c285MFF4X1RjZkZ1QlJ5TlNsY1JzZVFpNXE0TURBTDl2V2xGaS10OHh5VGFVUkNfYWxHMFFRSThEVGZBM28?oc=5","date":"2025-11-25","type":"deal","source":"Pasadena Now","summary":"Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership - Pasadena Now","headline":"Local Pharmaceutical Company Earns $200 Million Milestone Payment in Sarepta Partnership","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPTnVadEd6V0VHMDQ1dGcySFVnWXRMMHRyMnFfV2FvS3ZoM3pHbzJXNTJ4dG01b0psQ0lUbll2cDA3cHh4X25Lb3BrSmJFMEE2SG5GSXNMYWF1TzZmbzE5aWwzQ0ZXZzVZejlFTmxHNUQ0NWJzcm9xa1hNVEwxemVHZ2xYV2N2RUIwZjNIYWJ0YkpBNG5kMUN0RjdobEFBcHVUQlhVUWR6cGVkUUx2NTJ5eEdFZnRPYzkwN0h4UzdRQjBUVERvZ2c?oc=5","date":"2025-11-24","type":"pipeline","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics - Arrowhead Pharmaceuticals, In","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxNNUM0N2d4V0VQU3BreE5TVmdBTWtsWkVhSEFqZ3FiY0RGNnd5Z2VwLUdlRjd2aHo0Q1FybnBuU3RmNlF3RW5VUmNzNE1BamhZRWY3aGtjaTQwSlZNcTB1NWF5QnVLQ2VsTm5fcDNqYUVWNkNuNUdtQVg1cm94Y0JZRl9DR3N2WDU4QVJFMG80YTczaXd2YmlPN3dsdzJ6OE1ERTRMczc2NlBWdXBsdExaLVB3OHRQTDA0eE1OdUl5dU1lQTYxU0pqQ3FXSQ?oc=5","date":"2025-11-04","type":"trial","source":"Reuters","summary":"Sarepta shares tumble on trial failure, weak Elevidys outlook - Reuters","headline":"Sarepta shares tumble on trial failure, weak Elevidys outlook","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQaXZocTJNVk9DcG1wRENobkc0eVJ5RlRxa1Qxb056eHlzb25FQVNtbzVSQ2dqaHp0NEhnVkppejVCMUVfZEpZQmRWSWRyTmhTT0lyR1VPNlY3SG9pN01KcU9fSTZDQXpJWTBwWTJKX3NYMzNSS2FKQ2d0NEI0NldGWXVBWTFEWDZVaVNSU3dKRHpkVXp1ZlNhRmFjTVF2Yi1uQTN3Z2VXNWhjNGtIT05HWlVhOFl4UVQtbG9GSHV3?oc=5","date":"2025-10-03","type":"earnings","source":"Seeking Alpha","summary":"Sarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian Play (SRPT) - Seeking Alpha","headline":"Sarepta: Q3 Earnings An Upcoming Catalyst, But Risks Undermine Any Contrarian Play (SRPT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxNTFRyYUpPMUtsdF9MeGtsSm03aDNGYUFzc1ZFN2ZkWGRFUWhTRzFaR0FWMENfWHpwSEpfV2E2ODNKanJNQ3doU0lib3NOaWxIVlBSYm9kQjNBdklsQ0xuRTRTckNxbEdhR0xUaERNSUlWOUJvdmstcFBINzJ3cmpXRkR5a3lpZ3A2RjlCaktfMjhTa0k5T1lOcjNacGdOT3U5WGlUc2MwQ1FDTXJwcm16eDRNbU1wLXU1RmRfdWF3SUhST0VJVFU5LXNLa1Jab1FvYjhjcHFQUU54SnBKYzFWRkw0dnJMckp2ZHlHMlVXVmt6MEltZ3ctSDJscFhYaE5VR2hGeTdnZ3ZkNmE5YjJZWG1QZ1RVMGJhU1Btc2RPa2phSi1nQXpjUUFnVDc1Q2hkUmNLYng0VUg1M2N4ejhYZzFHN0w?oc=5","date":"2025-08-13","type":"pipeline","source":"BioSpace","summary":"Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Million in Cash in Satisfaction of Milestone from Sarepta Therapeutics - BioSpace","headline":"Arrowhead Pharmaceuticals Redeems Approximately $50 Million of Arrowhead Stock and Will Receive Approximately $50 Millio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQREI4MGJpOU1lVGc1TnRnM0ktZnN6ZUt1MXZrbXk1NGVrRVFPZ1g5ekdFR1c1c19qWVA3cldGaHluN19zVXFrQ0pLNHMtS05STDRwOUNxcnBuRl9EVlcxemJKNFExLW5EQ1lYRkhiRDZwS25lenljT3ptZFRWU2pLSjdOSWNaUVZpSzUybEkzbE9wNmY4QUNFLVAxdXB5V3RUZWJoVzJTT3RzenUtOUFTSWs3bTY?oc=5","date":"2025-07-28","type":"deal","source":"Bloomberg.com","summary":"Sarepta Owes $100 Million to Partner as Financial Pressure Grows - Bloomberg.com","headline":"Sarepta Owes $100 Million to Partner as Financial Pressure Grows","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNcl9qVU1wcEtZckVlZE92dldCXzRWNHU5T1pqRGFDTlpuSTZiQ2ZpX2hhU2UtOVlyUERMY1hkeDBQc1hHVy1qQlRBWnU1bmhVNW5aMmFQN3VtY2JvNUR2cjhTczBZcXp3cnVCeVlMSTlfdEUxNTA4VXgzZ1g5aDhyb2M3czVoRGdCRXpzRE9aNV95MEw0eHBIZFE5YXV3ektYUVZDR2RtR1ZnM1VPZUtHYXN5SHlWdVVaZEt2U0F3YmQ4RDRvOXc?oc=5","date":"2025-07-28","type":"pipeline","source":"Arrowhead Pharmaceuticals, Inc.","summary":"Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Arrowhead Pharmaceuticals, Inc.","headline":"Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics - Arrowhead Pharmaceuticals, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxOXzNRUGZxVk5jZ3FXd2hGREl2UXVxcUpiSjBSRm1WRlpjZXdsMEJkdmItTFZhOXRqTzJLOS0zZEVkLWR6M3R2eTdORDhiWHlnWEZvQThGRFZmOXE3ZmRUNkFvQ0dnV043UF9hNDRsN1JmMjg5Y0wyeURubmNsVHV0aWhlN3dVc3hCT2k3MXNWU3pkQlNBa0N0YjZBY2FMVEthY2RXRlJjWF8wT2hDRUxWTkthZGN6ZERWbkJxZzFnMjBBb0RqZnMyTUM3V1AxX1N6T2ROVEdkVjQ1cXAxUHBDY2ZENzZTSlk?oc=5","date":"2025-07-23","type":"deal","source":"Reuters","summary":"Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks - Reuters","headline":"Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNZXY1NzZDM2tWT3p2a3hDMld3RUYySmtPdHE3Q0tzQlBKaUJ4dUtfcXplWlRqc05HaHgwZ1pqb1NrTGJHX0d3NVZtZUdxa1lOamZoWC1zNm54THFheUJ5SFpoSjV3b21hU0ZKbFlldTYwTTkyYlo0T2tKejdSVlJlZF81eml0Y1VnckJkdXZvWFdvUVB0M29SNWJXSHZNcGR5Y3I4Qm95TWstdkRZZzNtajZuazR3bTI2bUNTOVdn?oc=5","date":"2025-07-21","type":"regulatory","source":"Fierce Pharma","summary":"Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market - Fierce Pharma","headline":"Sarepta stands behind Elevidys after FDA requests gene therapy be pulled from market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNRkpDdjZLQ1JOaF9JYUpRYmlxQjA4VTd0aUpDRVIyZnJfckw4NWYtNTJjQVRtb3JMcnpoaVR6bjlTbXd2YjAxNFNRbDJtUERRT1FvdG1ENXA0dkVUOHl2X3M0LUphTzJyUzRVUEdVMW1fRjRRZ0tSVk9PbHhuZURjc0I5UEZvOHhyejVtQldUMm1NNERVLVlKcmV2ckNua0pUX2VXNjVfSk5qdw?oc=5","date":"2025-07-16","type":"pipeline","source":"Fierce Biotech","summary":"Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning - Fierce Biotech","headline":"Sarepta pivots to siRNA and lays off 500 staffers as Elevidys gets box warning","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"phase_3":3,"phase_1":3},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}